Reformation reminderReFormation Pharmaceuticals ReFormation Pharmaceuticals is led by scientist, founder, CEO and chief science officer, Professor Jagdeep Nanchahal, of the University of Oxford. ReFormation Pharmaceuticals has identified a molecule (HMGB1) that primes the body's own stem cells to accelerate repair and regeneration following acute or chronic injury. The scientists combine this molecule and a synthetic non-psychoactive cannabinoid, which they are developing into a first-in-class therapy. Resinco Capital Partners (RSCZF) (CSE: RIN) just fully acquired ReFormation Pharmaceuticals. "Many pharma companies had programs in cannabis receptors, but did not pursue their efforts until now. They have deep pockets and good starting points, saving themselves several years of research. Companies like ReFormation Pharmaceuticals, a second generation medical marijuana company, has the upper hand against new pharmaceuticals that will take an average of 10 years to develop a drug," said Alex Somjen, Resinco CEO.